Bayer Sues Johnson & Johnson And Janssen Biotech Over Allegedly Misleading Prostate Cancer Drug Data

Bayer files false advertising suit against J&J and Janssen Biotech Lawsuit seeks preliminary and permanent injunctions in addition to damages. ...

February 25, 2026 | Wednesday | News
ImmunityBio Expands Global Footprint with ANKTIVA Commercialization Partnership in Middle East

Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio establi...

February 24, 2026 | Tuesday | News
Dr. Reddy’s Advances Biosimilar Pipeline with FDA Review Acceptance for DRL_AB

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “D...

February 24, 2026 | Tuesday | News
Sai Life Sciences Announces Major Talent Expansion as Global Outsourcing Momentum Accelerates

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organiza...

February 24, 2026 | Tuesday | News
Savara Advances MOLBREEVI Toward Approval with FDA Priority Review and 2026 Decision Timeline

Priority Review Granted, Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 22, 2026 -- -- Company Plans to Submit the MOLBREEV...

February 24, 2026 | Tuesday | News
Stellaromics Launches Pyxa™, the First Commercial Platform for Multiplexed 3D Spatial Transcriptomics in Intact Tissue

Stellaromics launched Pyxa™, the first commercially available platform to deliver multiplexed 3D spatial transcriptomics in intact tissue up to 100...

February 23, 2026 | Monday | News
Bio Usawa and Nanoly Bioscience Partner to Revolutionize Biologic and Vaccine Distribution with DynaShield™

Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization,  announced a defin...

February 19, 2026 | Thursday | News
Novartis’ Remibrutinib Demonstrates Strong Phase III Efficacy in Chronic Inducible Urticaria

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a hi...

February 19, 2026 | Thursday | News
Sapu Bioscience Secures Global IP Fortress for OT-101, Advancing Integrated CNS Platform in Neurology and Oncology

Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...

February 18, 2026 | Wednesday | News
InnoCare Pharma Doses First Patient in Phase II/III Trial of Soficitinib for Chronic Spontaneous Urticaria

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced &nb...

February 17, 2026 | Tuesday | News
QuidelOrtho Strengthens Global Immunoassay Portfolio Through Strategic Agreement With Lifotronic Technology

QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 68838...

February 17, 2026 | Tuesday | News
Alto Neuroscience, Inc. Completes Patient Enrollment in Phase 2 Trial of ALTO-101 for Schizophrenia-Related Cognitive Impairment

-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...

February 16, 2026 | Monday | News
Sanofi Appoints Belén Garijo as CEO, Signaling Bold Leadership Shift to Strengthen Innovation and Performance

Belén Garijo to become Chief Executive Officer of Sanofi Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Direc...

February 13, 2026 | Friday | News
Apimeds and Lōkahi Therapeutics Secure FDA Type C Meeting for LT-100 in Osteoarthritis

Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Ad...

February 13, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close